文档介绍：强直性脊柱炎与HLA-B27
【中图分类号】【文献标识码】A 【文章编号】1672-3783(2019)08-03--01
强直性脊柱炎( ankylosing spondylitis,AS) 是一种发效,能够有效改善临床症状,降低复发率。自2015年以来,AS的治疗管理取得了显著进展。新的治疗方法和策略包括使用肿瘤坏死因子抑制剂,白细胞介素抑制剂及Janus激酶抑制剂等。
在过去几年进行的大量调查和研究,提高了对AS发病机制的理解。这有助于开发新的治疗策略,从而改善患者的生活质量和寿命。随着技术的发展和研究的深入,对疾病的了解也越来越多,AS的发病机制以及诊断、治疗和病程监测将会取得重大进展,也将实现对疾病的更有效控制。
参考文献
Braun J, Siepe RJ. Ankylosing ,2007, 369: 13791390.
Cho H,Kim T,Kim T H,et al. Spinal mobility,vertebral squaring,pulmonary function,pain,fatigue,and quality of life in patients with ankylosing Rehabil Med,2013,37 ( 5) : 675682. Chen B, Li J, He C, et al. : Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review). Mol Med Rep. 2017;15(4):1943–51.
Reveille JD: The genetic basis of ankylosing spondylitis. Curr Opin Rheumatol. 2006;18(4):332–41.
Rubin LA, Amos CI, Wade JA, et al. : Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. Arthritis Rheum. 1994;37(8):1212–20.
Cortes A, Pulit SL, Leo PJ, et al. : Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nat Commun. 2015;6: 7146.
Ozen G, Deniz R, Eren F, et al. : Association of ERAP1, IL23R and PTGER4 Polymorphisms with Radiographic Severity of Ankylosing Spondylitis.